Curtiss Wright Corp: Form 10-Q for the period ended Sep 30, 2020
Filed with the SEC on Oct 29, 2020 and accepted by EDGAR at Oct 29, 2020, 11:49 ET.
Management's discussion and analysis
As filed, 1,375 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The following table provides information about our repurchase of equity securities that are registered by us pursuant to Section 12 of the Securities Exchange Act of 1934, as amended, during the quarter ended September 30, 2020.
| Total Number of shares purchased | Average Price Paid per Share | Total Number of Shares Purchased as Part of a Publicly Announced Program | Maximum Dollar amount of shares that may yet be Purchased Under the Program | |
|---|---|---|---|---|
| July 1 - July 31 | 49,383 | $89.10 | 1,281,147 | $71,142,791 |
| August 1 - August 31 | 41,514 | 101.18 | 1,322,661 | 66,942,555 |
| September 1 - September 30 | 43,025 | 97.62 | 1,365,686 | 62,742,269 |
| For the quarter ended September 30, 2020 | 133,922 | $95.58 | 1,365,686 | $62,742,269 |
In October 2020, the Corporation announced that its Board of Directors has authorized an additional $200 million for future share repurchases, increasing total available authorization to $250 million. The Corporation intends to use $50 million of the available authorization for opportunistic share repurchases through the remainder of the year. The Corporation had previously completed a $100 million opportunistic share repurchase program executed in March 2020 and expects to complete its existing $50 million 10b5-1 share repurchase program authorized for 2020 by the end of the year.
Market risk
As filed, 411 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Except for the broad effects of COVID-19 as a result of its negative impact on the financial markets, there have been no material changes in our market risk during the nine months ended September 30, 2020. Information regarding market risk and market risk management policies is more fully described in item “7A.Quantitative and Qualitative Disclosures about Market Risk” of our 2019 Annual Report on Form 10-K.
Controls and procedures
As filed, 1,497 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
As of September 30, 2020, our management, including our Chief Executive Officer and Chief Financial Officer, conducted an evaluation of our disclosure controls and procedures, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Based on such evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective as of September 30, 2020 insofar as they are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms, and they include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
During the quarter ended September 30, 2020, there have been no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Risk factors
As filed, 4,661 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2019, which could materially affect our business, financial condition, or future results. There have been no material changes in the Company’s risk factors from the aforementioned 10-K, except as set forth in the below risk factor.
The COVID-19 pandemic has adversely impacted and poses risks to our business, the nature and extent of which are highly uncertain and unpredictable.
In March 2020, the World Health Organization characterized the outbreak of COVID-19 as a pandemic. While we continue to actively monitor the pandemic and take steps to mitigate the risks posed by its spread, there is no guarantee that our efforts will mitigate the adverse impacts of COVID-19 or will be effective.
The pandemic has adversely affected, and is expected to continue to adversely affect, certain elements of our business, including our supply chain and production levels. We have experienced operational interruptions as a result of COVID-19, including the temporary suspension of operations due to government imposed restrictions at our facilities in Mexico and India. As of September 30, 2020, all of our manufacturing operations have resumed, but we are unable to predict if there will be additional government imposed restrictions on our ability to operate in future periods. Additionally, certain portions of our workforce might not be able to work effectively due to quarantines, government orders and guidance, travel restrictions, and other precautionary measures and restrictions. This could have an adverse effect on the productivity and profitability of such manufacturing facilities, which could in turn adversely impact our business and operations.
We also have experienced and expect to continue to experience unpredictable volatility in demand in our commercial aerospace and general industrial end markets. Several countries, including the United States, have taken steps to restrict air travel, along with many companies, including us, adopting policies which prohibit non-essential business travel by their employees. Even in the absence of formal restrictions and prohibitions, contagious illness and fear of contagion adversely affects travel behavior. Approximately 17% of our net sales for the year ended December 31, 2019 were derived from sales to commercial aerospace customers. Current travel restrictions, as well as changes in the propensity for the general public to travel by air as a result of the COVID-19 pandemic, have caused reductions in demand for commercial aircraft, which will adversely impact our net sales and operating results and may continue to do so for an extended period of time. In addition, an overall reduction in business activity as a result of the disruption caused by COVID-19 has led to a decrease in sales to the general industrial market, which primarily includes industrial vehicle and industrial valve products. Approximately 23% of our net sales for the year ended December 31, 2019 were derived from sales to the general industrial market. While we are unable to predict the magnitude of such impact at this time, the loss of, or significant reduction in, purchases by our large commercial aircraft manufacturers and general industrial customers could have a material adverse effect on our business, financial condition, and results of operations.
If the pandemic continues and conditions worsen, we may continue to experience additional adverse impacts on our operational and commercial activities, costs, customer orders, and collections of accounts receivable, which may be material. In addition, we may also incur additional costs to remedy damages caused by business disruptions, performance delays or interruptions, or payment defaults or bankruptcy of our third-party customers and suppliers, any of which could adversely affect our financial condition and results of operations. Furthermore, the pandemic has impacted and may further impact the broader economies of affected countries, including negatively impacting economic growth. Due to the speed with which the situation is developing, the global breadth of its spread and the range of governmental and community reactions thereto, there is uncertainty around its duration, ultimate impact, and the timing of recovery. Therefore, the pandemic could lead to an extended disruption of economic activity whereby the impact on our consolidated results of operations, financial position and cash flows could be material.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Cost of revenue | 3 months2020-07-01 to 2020-09-30 | $358.8m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2020-01-01 to 2020-09-30 | $1.12bn | us-gaap:CostOfRevenue |
| Gross profit | 3 months2020-07-01 to 2020-09-30 | $212.8m | us-gaap:GrossProfit |
| Gross profit | 9 months2020-01-01 to 2020-09-30 | $599.4m | us-gaap:GrossProfit |
| Research and development | 3 months2020-07-01 to 2020-09-30 | $17.6m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2020-01-01 to 2020-09-30 | $54.2m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2020-07-01 to 2020-09-30 | $84.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2020-01-01 to 2020-09-30 | $212.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2020-07-01 to 2020-09-30 | $9.1m | us-gaap:InterestExpense |
| Interest expense | 9 months2020-01-01 to 2020-09-30 | $25.1m | us-gaap:InterestExpense |
| Income tax | 3 months2020-07-01 to 2020-09-30 | $16.3m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2020-01-01 to 2020-09-30 | $46.8m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2020-07-01 to 2020-09-30 | $64.6m | us-gaap:NetIncomeLoss |
| Net income | 9 months2020-01-01 to 2020-09-30 | $147.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2020-07-01 to 2020-09-30 | $1.55 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2020-01-01 to 2020-09-30 | $3.49 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2020-07-01 to 2020-09-30 | $1.56 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2020-01-01 to 2020-09-30 | $3.52 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2020-07-01 to 2020-09-30 | 41,797,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2020-01-01 to 2020-09-30 | 42,190,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2020-01-01 to 2020-09-30 | $3.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2020-01-01 to 2020-09-30 | $36.3m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months2020-01-01 to 2020-09-30 | $14.2m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 9 months2020-01-01 to 2020-09-30 | $137.2m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2020-09-30 | $426.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-09-30 | $1.58bn | us-gaap:AssetsCurrent |
| Total assets | At period end2020-09-30 | $3.96bn | us-gaap:Assets |
| Current liabilities | At period end2020-09-30 | $665.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2020-09-30 | $2.16bn | us-gaap:Liabilities |
| Long-term debt | At period end2020-09-30 | $1.06bn | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2020-09-30 | $1.80bn | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2020-09-30 | 41,502,026 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0000026324-20-000032. Last ingested by Listed: Nov 5, 2026, 15:59 ET. Listed shows no prices and gives no investment advice.